Details for Patent: 7,122,566

Which drugs does patent 7,122,566 protect, and when does it expire?

Patent 7,122,566 protects SKELAXIN and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 7,122,566

Title:	Metaxalone products, method of manufacture, and method of use
Abstract:	Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.
Inventor(s):	Du; Jie (Lansdale, PA), Roberts; Richard H. (Lakewood, NJ)
Assignee:	Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:	11/364,468
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 7,122,566

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
King Pharms	SKELAXIN	metaxalone	TABLET;ORAL	013217-003	Aug 30, 2002		DISCN	Yes	No						TREATMENT OF MUSCULOSKELETAL CONDITIONS

International Family Members for US Patent 7,122,566

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2626027
World Intellectual Property Organization (WIPO)	2007094825